Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07041372

Cerebral Atherosclerosis Research With Positron Emission Tomography

The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:

* Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors? * Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.

Participants will:

* Undergo whole-body FDG PET once their neurological status has stabilized after stroke. * Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day. * Maintain regular clinic visits for up to 24 months following the index stroke

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Cerebral Infarction Brain Diseases Brain Infarction Brain Ischemia Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Infarction Ischemia Necrosis Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Stroke Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul National University Hospital

Seoul, Jong-ro Gu, 03080, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute ischemic stroke patients who admitted within seven days after symptom onset

Exclusion criteria

  • Patients with unstable vital signs or neurological symptoms
  • Patients with estimated glomerular filtration rate less than 30ml/min
  • Patients with uncontrolled diabetes requiring persistent insulin injection
  • During pregnancy or while breastfeeding
  • Patients with impaired consent capacity
  • Patients with diagnosed/treatment for dementia
  • Patients undergoing treatment for malignant tumors or serious autoimmune diseases

Treatment and study plan

FDG-PET

Diagnostic Test

The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.

Primary outcomes

  1. Vascular events

    Time frame: up to 24 months after index stroke

    Stroke, myocardial infarction, vascular death

Secondary outcomes

  1. overall vascular events

    Time frame: up to 24 months after index stroke

    primary vascular events plus transient ischemic attack, venous thromboembolism, peripheral artery disease requiring intervention or hospitalization

Other outcomes

  1. Overall events

    Time frame: up to 24 months after index stroke

    fracture, cancer, bleeding, dementia, overall death

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Acronym: CARPET

Important dates

Study start
2021
Primary completion
2029
Study completion
2029
First posted
Jun 27, 2025
Registry last updated
Jun 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.